MedTrace Logo

Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients

NCT05043675 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-09-14

No results posted yet for this study

Summary

The overall objective of this study is to evaluate the overall pattern of \[18F\]APN-1607 uptake in subjects with AD dementia

Conditions

  • Alzheimer Disease

Interventions

DRUG

[18F]APN-1607

Subjects will receive one injection of \[18F\]APN-1607 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibrillar tau. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Feng Wang · Nanjing First Hospital, Nanjing Medical University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2024-09-10
Completion
2024-09-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043675 on ClinicalTrials.gov